Cohance Lifesciences reports zero USFDA observations at API facility

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, informed the stock exchanges on September 11, 2025, about the successful completion of a United States Food and Drug Administration (USFDA) inspection at its API manufacturing facility (API Unit-1) in Jaggaiahpet, Andhra Pradesh. The audit, focusing on current Good Manufacturing Practices (cGMP), took place from September 8, 2025, to September 11, 2025.

The company reported that the inspection concluded with zero Form 483 observations, indicating full compliance with regulatory standards. Cohance Lifesciences reiterated its commitment to maintaining high standards of quality and regulatory compliance across its operations, aiming to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.